An 8 year old girl with partial duplication of the short arm of chromosome 17 (_7Med Genet 1998;35:169-172) 
Partial trisomy for the short arm of chromosome 17 is relatively rare. ' 12 The clinical findings in reported cases were pre-and posmatal growth retardation, craniofacial abnormalities including microcephaly, hypertelorism, micrognathia, apparently low set ears, high arched palate, and a short, webbed neck, flexion abnormalities of the fingers, and foot abnormalities. Localised to 17p are four disorders that could result from alterations in gene dosage. Miller-Dieker syndrome (MDS) and Smith-Magenis syndrome (SMS) involve deletion of 17p 13.3 and 17p 1.2, respectively. 3 14 Charcot-Marie-Tooth type 1A (CMT1A) is a demyelinating peripheral neuropathy that is commonly associated with a submicroscopic duplication of 17p 11.2p1 2."' Hereditary neuropathy with liability to pressure palsies (HNPP) is associated with a deletion resulting from a reciprocal recombinant product of the CMT1A duplication.16 18 The specific features of CMT1A are progressive distal muscle atrophy, weakness of the feet and hand deformities which appear later, gait abnormalities, and a completely penetrant electrophysiological phenotype of symmetrical reduction in motor nerve conduction velocity (NCV <40 m/s)."
The frequent 1 to touch. (fig 1 B) . To assess the extent of the duplication, Charcot-MarieTooth syndrome (D17S122) ( fig 1C) and p53, a tumour suppressor gene probe ( fig 1D) were used. Two copies of each probe were detected on the duplicated 17p. The Smith-Magenis region probe (D17S29) gave only one signal (fig lE) . Therefore, the duplication is tandem and includes the region distal to DI 7S29 and beyond D17S379. Both parental peripheral blood karyotypes were normal. Therefore, the duplication in the proband is most probably a de novo event.
Discussion
Partial trisomy of 17p because of a duplication is most often tandem and occasionally inverted. The clinical findings in reported patients are intrauterine and postnatal growth retardation, developmental delay, mental retardation, craniofacial abnormalities, and limb deformities.'1 2 The features may vary depending on the extent of the duplication. Although 17p is involved in four known disorders, Miller-Dieker syndrome (MDS), SmithMagenis syndrome (SMS), Charcot-MarieTooth type IA (CMT1A), and hereditary neuropathy with liability to pressure palsies (HNPP), CMT1A is the only one that is a duplication syndrome. Therefore, 17p duplication cases should be tested for CMT1A duplication and motor nerve conduction velocity.
Patients with mosaic trisomy 17p are extremely rarely reported. Shabtai et a!f7 described a 20 month old child with pure trisomy 17pll.2pl3.3 in 60% of lymphoblasts. The clinical findings were psychomotor retardation, hypotonia, frontal bossing, low set and malformed ears, ptosis, micrognathia, and antimongoloid slant of the eyes. Morrison et alf8 reported a mosaic partial trisomy 17 resulting from a ring chromosome identified by FISH to have a breakpoint probably distal to the SmithMagenis region and proximal to the MillerDieker region. The ring was found in 13% of the lymphoblasts (6/45). This patient was a 3 year old girl who had feeding difficulties and bilateral dislocation of the hips. Delayed speech and motor skills were observed. Her eyes were deep set and she had macroglossia and macrostomia. Limb defects included a smaller right hand than the left, long, narrow feet, generalised joint laxity, and scoliosis. The present case has psychomotor and speech delay, microcephaly, high arched palate, a systolic murmur, renal abnormality, and bilateral hernias, which are features recorded in other cases with trisomy 17p. The recent development of foot abnormalities and the symmetrical decrease in nerve conduction velocity is consistent with CMT1A. Although, this supports a gene dosage mechanism for CMT1A, the mosaicism (20% lymphoblasts, 100% fibroblasts) raises questions about the proportion of neurones with the duplication that are necessary for phenotypic manifestation. The clinical picture suggests that the neurones probably have a high percentage or almost all abnormal dup(17) cells as observed in the fibroblasts. However, if a peripheral nerve biopsy had been available, the mosaic distribution of the duplication 17p, the neuronal histopathology of onion bulb formation, and the decreased axonal compared to fibre diameter could have been assessed. Although the percentage of abnormal cells in the blood was low, this appears to have no obvious impact on the CMT1A neuropathy.
The only other report of a child of comparable age with mosaicism involved full trisomy 17 of the fibroblasts at first evaluation and in 80% of the fibroblasts five years later. Based on two mosaic cases29 (present study), partial or complete trisomy 17 appears to be better tolerated by fibroblasts than lymphoblasts. The precedent for preferential expression of mosaicism in fibroblasts has been observed in cases of trisomy 8, 9, and tetrasomy 12p. The clinical implications are that if there are strong clinical grounds for suspecting trisomy 17, a negative blood chromosome study probably should be pursued with cytogenetic analysis of skin fibroblasts. Similarly, for confirmation of prenatal mosaic full trisomy 17 or trisomy 17p, a normal blood chromosome result should be ascertained in fibroblasts. Paediatric cases with partial duplication of 17p should be tested for duplication of the CMT1A region. The parents of probands with the duplication need to be counselled about the child having CMT1A later in life (mean 12 years (SD 7.3)). In mosaic cases with a CMT1A duplication, a nerve conduction velocity study will be necessary to ascertain the manifestation of CMT1A.
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